Open AccessStudy of IL‐2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma
Author(s) -
MOUAWAD R.,
ICHEN M.,
RIXE O.,
BENHAMMOUDA A.,
VUILLEMIN E.,
WEIL M.,
KHAYAT D.,
SOUBRANE C.
Publication year - 1994
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1994.tb06092.x
Subject(s) - chemoimmunotherapy , melanoma , flow cytometry , medicine , alpha chain , receptor , alpha interferon , immunology , immunotherapy , receptor expression , alpha (finance) , cancer research , beta (programming language) , interferon alfa , interferon , oncology , immune system , surgery , construct validity , computer science , patient satisfaction , programming language
SUMMARY Using flow cytometry. cellular IL‐2 receptors were studied before and following chemoimmunotherapy combination in 20 patients with metastatic malignant melanoma (MMM). Patients received cisplatin (100 mg m 2 ) at days 1 and 28, recombinant IL‐2 by continuous infusion from days 3 to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon‐alpha (IFN‐±) was given subcutaneously three times weekly. In terms of clinical response, we observed 55% objective response (complete: 15%), When pretreatment blood samples were compared with those of healthy donors, we did not observe any change in low (α chain) and high affinity receptor (α+β) expression. In contrast, intermediate affinity p75 (β chain) expression was decreased significantly (P ≤ 0.0001) in MMM patients. During treatment, we found a dramatic increase of β chain as well as high affinity (α+β) expression in responding patients, as soon as IL‐2 therapy began. Furthermore, the increase of β chain expression was limited to natural killer (NK) cells (CD56 + ). In non‐responding patients, on the other hand, increase of both receptors was seen only at day 31. These data suggest the involvement of β chain expression in the mechanism of cell activation after chemoimmunotherapy. Moreover, this early 3 chain expression is correlated with the clinical response to chemoimmunotherapy.